546. Therapeutic Effect of Regdanvimab in Patients with Mild to Moderate COVID-19: Day 28 Results from a Multicentre, Randomised, Controlled Pivotal Trial

BACKGROUND: Regdanvimab is a monoclonal antibody with activity against SARS-CoV-2. A Phase 2/3 study with two parts is currently ongoing and data up to Day 28 of Part 1 is available while the data from 1315 patients enrolled in Part 2 are expected in June 2021. METHODS: This phase 2/3, randomized, p...

Descripción completa

Detalles Bibliográficos
Autores principales: Ison, Michael G, Kim, Jin Yong, Sandulescu, Oana, Preotescu, Liliana-Lucia, Martinez, Norma Erendira Rivera, Dobryanska, Marta, Birlutiu, Victoria, Miftode, Egidia Gabriela, Gaibu, Natalia, Caliman-Sturdza, Olga Adriana, Florescu, Simin-Aysel, Streinu-Cercel, Anca, Lee, Sang Joon, Kim, Sung Hyun, Chang, Il Sung, Bae, Yun Ju, Suh, Jee Hye, Kim, Mi Rim, Chung, Da Re, Kim, Sun Jung, Lee, Seul Gi, Park, Ga Hee, Eom, Joong Sik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644524/
http://dx.doi.org/10.1093/ofid/ofab466.745

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644524/
http://dx.doi.org/10.1093/ofid/ofab466.745

Ejemplares similares